Tags

Type your tag names separated by a space and hit enter

[Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Schweiz Rundsch Med Prax. 1992 Aug 25; 81(35):1011-5.SR

Abstract

Apomorphine, a dopamine-agonist was applied as s. c. infusions to 7 patients with idiopathic Parkinson's disease. The indications were longlasting akinetic episodes (4 patients) and therapeutically resistant invalidating motoric fluctuations ("on-off") as well as hyperkinesia (3 patients) on anti-Parkinson medication. The effect of apomorphine as an anti-Parkinson therapeutic was verified using clinical scales and a portable activity-monitoring device. The s. c. infusion therapy (20-90 mg/die, or 0.025-0.01 mg/kg/die respectively) was effective in the akinetic patients interrupting akinesia and the inability to swallow. An improvement was also registered in patients with "on-off" and hyperkinesia using longlasting subcutaneous apomorphine infusions. The therapy was continued over a longer period of time with 2 patients as outpatients. The side-effects were nausea and local subcutaneous indurations at sites of infusions.

Authors+Show Affiliations

Neurologische Klinik, Universitätsspital Zürich.No affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

ger

PubMed ID

1410978

Citation

Albani, C, et al. "[Subcutaneous Apomorphine Infusion in the Treatment of Parkinson Disease]." Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis, vol. 81, no. 35, 1992, pp. 1011-5.
Albani C, Zangger I, Fischer G. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease]. Schweiz Rundsch Med Prax. 1992;81(35):1011-5.
Albani, C., Zangger, I., & Fischer, G. (1992). [Subcutaneous apomorphine infusion in the treatment of Parkinson disease]. Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis, 81(35), 1011-5.
Albani C, Zangger I, Fischer G. [Subcutaneous Apomorphine Infusion in the Treatment of Parkinson Disease]. Schweiz Rundsch Med Prax. 1992 Aug 25;81(35):1011-5. PubMed PMID: 1410978.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Subcutaneous apomorphine infusion in the treatment of Parkinson disease]. AU - Albani,C, AU - Zangger,I, AU - Fischer,G, PY - 1992/8/25/pubmed PY - 1992/8/25/medline PY - 1992/8/25/entrez SP - 1011 EP - 5 JF - Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis JO - Schweiz Rundsch Med Prax VL - 81 IS - 35 N2 - Apomorphine, a dopamine-agonist was applied as s. c. infusions to 7 patients with idiopathic Parkinson's disease. The indications were longlasting akinetic episodes (4 patients) and therapeutically resistant invalidating motoric fluctuations ("on-off") as well as hyperkinesia (3 patients) on anti-Parkinson medication. The effect of apomorphine as an anti-Parkinson therapeutic was verified using clinical scales and a portable activity-monitoring device. The s. c. infusion therapy (20-90 mg/die, or 0.025-0.01 mg/kg/die respectively) was effective in the akinetic patients interrupting akinesia and the inability to swallow. An improvement was also registered in patients with "on-off" and hyperkinesia using longlasting subcutaneous apomorphine infusions. The therapy was continued over a longer period of time with 2 patients as outpatients. The side-effects were nausea and local subcutaneous indurations at sites of infusions. SN - 1013-2058 UR - https://www.unboundmedicine.com/medline/citation/1410978/[Subcutaneous_apomorphine_infusion_in_the_treatment_of_Parkinson_disease]_ L2 - http://www.diseaseinfosearch.org/result/5603 DB - PRIME DP - Unbound Medicine ER -